Image For Activity Cover
Management of Other Substance Use Co-occurring with Opioid Use Disorder: Benzodiazepines, Cocaine and Amphetamines, and Cannabis
SUD 101 Core Curriculum Overview

Curriculum overview:  While healthcare professionals are often on the front lines of treating substance use disorders, most have limited (if any) training in this area. The SUD 101 Core Curriculum was created to provide a foundation of the current research, resources, and support needed to increase healthcare professionals’ competence and confidence in the care of their patients across the continuum of care. This activity, Management of Other Substance Use Co-occurring with Opioid Use Disorder: Benzodiazepines, Cocaine and Amphetamines, and Cannabis, is part of the 23-module curriculum. Please see below for a summary of module 16 out of 23:
Module 16 Overview
Title: Management of Other Substance Use Co-occurring with Opioid Use Disorder: Benzodiazepines, Cocaine and Amphetamines, and Cannabis 

Presenter(s):
 
Edward V. Nunes, MD, Columbia University Medical Center

Module Description: This educational activity reviews other substance use disorders that often co-occur with opioid use disorder (OUD), including benzodiazepines and other tranquilizers, cocaine and stimulants, and cannabis. The presentation will also discuss principles of diagnosis and evaluation of treatment for each of these by themselves, and in the context of OUD. 

Educational Objectives:

  • Diagnose and formulate a treatment plan for misuse and use disorders of the following substances, with emphasis on when they co-occur with opioid use disorder:
    • Benzodiazepines
    • Cocaine, methamphetamine, etc
    • Cannabis
Summary
Availability: On-Demand
Expires on Jan 12, 2026
Cost: FREE
Credit Offered:
1 CME Credit
1 PA-CME Credit
1 Other Professionals Credit
1 Nursing Credit
1 Pharmacy Credit
1 IPCE Credit
Recommended
 
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.



Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

 
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
For Buprenorphine Training Inquiries, email PCSS-MOUD.

ORN
opioidresponsenetwork.org

Powered By